» Articles » PMID: 25335433

Regulatory T Cells from Active Non-segmental Vitiligo Exhibit Lower Suppressive Ability on CD8+CLA+ T Cells

Overview
Journal Eur J Dermatol
Specialty Dermatology
Date 2014 Oct 23
PMID 25335433
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent studies have shown that vitiligo is a T-cell mediated autoimmune disease. Skin-homing cytotoxic T lymphocytes expressing cutaneous lymphocyte-associated antigen (CLA) have been suggested to be responsible for the destruction of melanocytes in vitiligo. An aberration in the suppressive function of regulatory T cells (Tregs) has been reported in vitiligo patients. However, whether the weakened suppressive ability of the Tregs contributes to hyper-activated skin homing CD8(+)CLA(+) T cells remains to be determined.

Objectives: To investigate the inhibition of circulating Tregs on the proliferation of autologous CD8(+)CLA(+) T cells in non-segmental vitiligo patients.

Methods: CD8(+)CLA(+) T cells and Tregs were obtained from the peripheral blood of 13 non-segmental vitiligo patients and 7 controls. The proliferative responses of CD8(+)CLA(+) T cells were assessed in the absence or presence of autologous Tregs, and the levels of Transforming Growth Factor β1(TGF-β1) and IL-10 in culture supernatants were detected by enzyme-linked immunosorbent assay.

Results: The proliferative responses of circulating CD8(+)CLA(+) T cells in the presence of Tregs were significantly higher in the active vitiligo than in the stable vitiligo and control groups. Tregs from active vitiligo patients exhibited a lower inhibitory effect on proliferation of CD8(+)CLA(+) T cells. The levels of TGF-β1 produced by Tregs were significantly lower in active vitiligo than other groups and anti-TGF-β1 antibodies could abrogate the suppressive function of Tregs.

Conclusions: The functional activity of Tregs is compromised in active vitiligo patients. TGF-β1 plays an important role in the autoimmune mechanism of the disease.

Citing Articles

Insights into the gut microbiome of vitiligo patients from India.

Kumar S, Mahajan S, Kale D, Chourasia N, Khan A, Asati D BMC Microbiol. 2024; 24(1):440.

PMID: 39468434 PMC: 11514916. DOI: 10.1186/s12866-024-03529-5.


Dopamine, Immunity, and Disease.

Channer B, Matt S, Nickoloff-Bybel E, Pappa V, Agarwal Y, Wickman J Pharmacol Rev. 2023; 75(1):62-158.

PMID: 36757901 PMC: 9832385. DOI: 10.1124/pharmrev.122.000618.


Immunometabolism in the pathogenesis of vitiligo.

Lyu C, Sun Y Front Immunol. 2022; 13:1055958.

PMID: 36439174 PMC: 9684661. DOI: 10.3389/fimmu.2022.1055958.


The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report.

Gao Z, Xu Y, Zu J, Wang X, Sun C, Qiu S Front Immunol. 2022; 13:946829.

PMID: 36052082 PMC: 9424493. DOI: 10.3389/fimmu.2022.946829.


Current Concepts of Vitiligo Immunopathogenesis.

Hlaca N, Zagar T, Kastelan M, Brajac I, Prpic-Massari L Biomedicines. 2022; 10(7).

PMID: 35884944 PMC: 9313271. DOI: 10.3390/biomedicines10071639.